Literature DB >> 22525208

Use of animal model of sepsis to evaluate novel herbal therapies.

Wei Li1, Shu Zhu, Yusong Zhang, Jianhua Li, Andrew E Sama, Ping Wang, Haichao Wang.   

Abstract

Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection. It has been routinely simulated in animals by several techniques, including infusion of exogenous bacterial toxin (endotoxemia) or bacteria (bacteremia), as well as surgical perforation of the cecum by cecal ligation and puncture (CLP). CLP allows bacteria spillage and fecal contamination of the peritoneal cavity, mimicking the human clinical disease of perforated appendicitis or diverticulitis. The severity of sepsis, as reflected by the eventual mortality rates, can be controlled surgically by varying the size of the needle used for cecal puncture. In animals, CLP induces similar, biphasic hemodynamic cardiovascular, metabolic, and immunological responses as observed during the clinical course of human sepsis. Thus, the CLP model is considered as one of the most clinically relevant models for experimental sepsis. Various animal models have been used to elucidate the intricate mechanisms underlying the pathogenesis of experimental sepsis. The lethal consequence of sepsis is attributable partly to an excessive accumulation of early cytokines (such as TNF, IL-1 and IFN-γ) and late proinflammatory mediators (e.g., HMGB1). Compared with early proinflammatory cytokines, late-acting mediators have a wider therapeutic window for clinical applications. For instance, delayed administration of HMGB1-neutralizing antibodies beginning 24 hours after CLP, still rescued mice from lethality, establishing HMGB1 as a late mediator of lethal sepsis. The discovery of HMGB1 as a late-acting mediator has initiated a new field of investigation for the development of sepsis therapies using Traditional Chinese Herbal Medicine. In this paper, we describe a procedure of CLP-induced sepsis, and its usage in screening herbal medicine for HMGB1-targeting therapies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22525208      PMCID: PMC3466661          DOI: 10.3791/3926

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  28 in total

Review 1.  Cytokines--soluble factors in immune responses.

Authors:  F Balkwill
Journal:  Curr Opin Immunol       Date:  1988-12       Impact factor: 7.486

2.  HMG-1 as a late mediator of endotoxin lethality in mice.

Authors:  H Wang; O Bloom; M Zhang; J M Vishnubhakat; M Ombrellino; J Che; A Frazier; H Yang; S Ivanova; L Borovikova; K R Manogue; E Faist; E Abraham; J Andersson; U Andersson; P E Molina; N N Abumrad; A Sama; K J Tracey
Journal:  Science       Date:  1999-07-09       Impact factor: 47.728

Review 3.  Sepsis and septic shock--a review of laboratory models and a proposal.

Authors:  K A Wichterman; A E Baue; I H Chaudry
Journal:  J Surg Res       Date:  1980-08       Impact factor: 2.192

4.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia.

Authors:  K J Tracey; Y Fong; D G Hesse; K R Manogue; A T Lee; G C Kuo; S F Lowry; A Cerami
Journal:  Nature       Date:  1987 Dec 17-23       Impact factor: 49.962

5.  Mixed bacterial infection model of sepsis in rabbits and its application to evaluate superantigen-adsorbing device.

Authors:  Mayumi Fukuyama; Keishi Miwa; Naoko Shibayama; Shinji Ogura; Takashi Nishiyama; Nobuhiro Maekawa
Journal:  Blood Purif       Date:  2005-01-06       Impact factor: 2.614

6.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

7.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

Authors:  E J Ziegler; C J Fisher; C L Sprung; R C Straube; J C Sadoff; G E Foulke; C H Wortel; M P Fink; R P Dellinger; N N Teng
Journal:  N Engl J Med       Date:  1991-02-14       Impact factor: 91.245

8.  Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia.

Authors:  M K Eskandari; G Bolgos; C Miller; D T Nguyen; L E DeForge; D G Remick
Journal:  J Immunol       Date:  1992-05-01       Impact factor: 5.422

9.  Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.

Authors:  E J Ziegler; J A McCutchan; J Fierer; M P Glauser; J C Sadoff; H Douglas; A I Braude
Journal:  N Engl J Med       Date:  1982-11-11       Impact factor: 91.245

10.  Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

Authors:  E Abraham; R Wunderink; H Silverman; T M Perl; S Nasraway; H Levy; R Bone; R P Wenzel; R Balk; R Allred
Journal:  JAMA       Date:  1995 Mar 22-29       Impact factor: 56.272

View more
  8 in total

1.  EGCG induces G-CSF expression and neutrophilia in experimental sepsis.

Authors:  Wei Li; Andrew H Wu; Shu Zhu; Jianhua Li; Rong Wu; John D'Angelo; Haichao Wang
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

2.  Carbenoxolone blocks endotoxin-induced protein kinase R (PKR) activation and high mobility group box 1 (HMGB1) release.

Authors:  Wei Li; Jianhua Li; Andrew E Sama; Haichao Wang
Journal:  Mol Med       Date:  2013-07-24       Impact factor: 6.354

Review 3.  Targeting HMGB1 in the treatment of sepsis.

Authors:  Haichao Wang; Mary F Ward; Andrew E Sama
Journal:  Expert Opin Ther Targets       Date:  2014-01-06       Impact factor: 6.902

4.  Serum Amyloid A Stimulates PKR Expression and HMGB1 Release Possibly through TLR4/RAGE Receptors.

Authors:  Wei Li; Shu Zhu; Jianhua Li; Jason D'Amore; John D'Angelo; Huan Yang; Ping Wang; Kevin J Tracey; Haichao Wang
Journal:  Mol Med       Date:  2015-06-02       Impact factor: 6.354

5.  Green tea catechins quench the fluorescence of bacteria-conjugated Alexa fluor dyes.

Authors:  Lin Zhao; Wei Li; Shu Zhu; Sheena Tsai; Jianhua Li; Kevin J Tracey; Ping Wang; Saijun Fan; Andrew E Sama; Haichao Wang
Journal:  Inflamm Allergy Drug Targets       Date:  2013-10

6.  Survival and Pulmonary Injury After Neonatal Sepsis: PD1/PDL1's Contributions to Mouse and Human Immunopathology.

Authors:  Eleanor A Fallon; Chun-Shiang Chung; Daithi S Heffernan; Yaping Chen; Monique E De Paepe; Alfred Ayala
Journal:  Front Immunol       Date:  2021-03-03       Impact factor: 7.561

7.  It Is Not Just Folklore: The Aqueous Extract of Mung Bean Coat Is Protective against Sepsis.

Authors:  Shu Zhu; Wei Li; Jianhua Li; Arvin Jundoria; Andrew E Sama; Haichao Wang
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-24       Impact factor: 2.629

8.  Pre-B cell leukemia transcription factor 3 induces inflammatory responses in human umbilical vein endothelial cells and murine sepsis via acting a competing endogenous RNA for high mobility group box 1 protein.

Authors:  Yunzhong Zhang; Jing Feng; Jizhen Cui; Guozheng Yang; Xianai Zhu
Journal:  Mol Med Rep       Date:  2018-02-15       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.